IBI133 targets HER3 on tumor cells, is internalized, and releases a topoisomerase I–inhibiting payload that induces DNA damage and apoptosis. Topoisomerase I is the intracellular enzymatic target, but killing is directed by HER3 binding, not by topoisomerase I expression itself.